Treg down-regulation could also have significant anti-cancer implications to be considered in the development of news coming oncologic immunotherapy trials with programmed cell death receptor-1 (PD-1)/PD-1 ligand-1 (PDL1) immune checkpoint monoclonal antibodies inhibitors. This evidence concerns the gene CD274 and cancer.